Valuation : Nectar Lifesciences Limited

Market Cap 2.39B 25.31M 21.84M 20.57M 18.74M 35.04M 35.3M 244M 94.52M 1.22B 95.06M 92.98M 4.02B P/E 2025
-4.53x
P/E 2026 -0.69x
Enterprise Value 1.14B 12.07M 10.41M 9.81M 8.94M 16.71M 16.83M 116M 45.07M 583M 45.33M 44.34M 1.92B EV / Sales 2025
0.64x
EV / Sales 2026 -
Free-Float
44.34%
Yield 2025 *
-
Yield 2026 -
Aug. 15 Nectar Lifesciences Limited Changes Its Corporate Office in Chandigarh CI
Aug. 14 Nectar Lifesciences Limited Announces Board and Committee Changes, Effective August 14, 2026 CI
Aug. 14 Nectar Lifesciences Limited Reports Earnings Results for the First Quarter Ended June 30, 2026 CI
Aug. 06 Nectar Lifesciences Limited Announces Resignation of Dr. Surulichamy Senthilkumar from Non-Executive Non-Independent Director, Effective August 06, 2026 CI
Jul. 11 Nectar Lifesciences Limited Announces Change in Registered Office Address CI
May. 30 Nectar Lifesciences Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2026 CI
Mar. 05 Nectar Lifesciences Limited completed the acquisition of Avensis Exports Private Limited. CI
Mar. 02 Nectar Lifesciences to acquire 100% paid-up equity share capital of Avensis Exports RE
Mar. 01 Nectar Lifesciences Limited agreed to acquire Avensis Exports Private Limited for INR 2.5 million. CI
Jan. 23 Nectar Lifesciences Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2025 CI
Jan. 15 Tranche Update on Nectar Lifesciences Limited's Equity Buyback Plan announced on December 3, 2025. CI
Jan. 05 Nectar Lifesciences Limited's Equity Buyback announced on May 6, 2023, has closed with 30,000,000 shares, representing 13.38% for INR 810 million. CI
Dec. 19 Capnest Health Care Private Limited entered into Business Transfer agreement to acquire Empty Hard Gelatin Capsule unit at Bhatoli from Nectar Lifesciences Limited for approximately INR 200 million. CI
1 day+1.48%
1 week+8.65%
Current month-1.83%
1 month+16.35%
3 months+1.82%
6 months+0.90%
Current year-36.58%
1 week 11.66
Extreme 11.66
13.5
1 month 10.05
Extreme 10.05
13.5
Current year 9.3
Extreme 9.3
20.9
1 year 9.3
Extreme 9.3
22.4
3 years 9.3
Extreme 9.3
56.5
5 years 9.3
Extreme 9.3
56.5
10 years 7.1
Extreme 7.1
56.5
Manager TitleAgeSince
Director of Finance/CFO 68 2022-11-13
Compliance Officer - 2025-03-31
Director TitleAgeSince
Chairman 66 1995-06-26
Director/Board Member 69 2019-02-10
Director/Board Member 75 2021-09-20
Date Insider Type Main position Quantity % Market Cap. Importance
12/19/24 Buy 400,000 0.1784%
Change 5-day change 1-year change 3-year change Capi.($)
+1.48%+8.65%-13.43%-53.46% 24.83M
+0.14%+0.50%+23.57%+74.18% 48.77B
-1.61%+0.83%+53.64%+120.47% 40.67B
-1.16%+2.64%+16.46%+88.00% 12.27B
-0.72%-0.65%-10.99%+13.44% 12.11B
+0.57%+1.73%+31.59%+153.11% 9.28B
-2.36%-3.76%+23.20%+43.34% 7.55B
-0.42%+2.50%+27.67%+224.95% 7.35B
-0.62%+0.45%+45.04%-10.78% 7.3B
-1.29%-1.44%-41.24%+14.36% 5.25B
Average -0.60%+1.42%+15.55%+66.76% 15.06B
Weighted average by Cap. -0.72%+1.17%+27.78%+87.37%

Financials

2025 2026
Net sales 16.7B 177M 153M 144M 131M 245M 247M 1.7B 660M 8.54B 664M 649M 28.05B -
Net income -1.14B -12.03M -10.38M -9.78M -8.91M -16.66M -16.78M -116M -44.94M -581M -45.19M -44.2M -1.91B -2.93B -31.01M -26.75M -25.2M -22.96M -42.91M -43.23M -298M -116M -1.5B -116M -114M -4.92B
Net Debt 5.62B 59.52M 51.35M 48.37M 44.07M 82.38M 83M 573M 222M 2.87B 224M 219M 9.44B -1.25B -13.24M -11.43M -10.76M -9.81M -18.33M -18.47M -127M -49.45M -640M -49.73M -48.64M -2.1B
Logo Nectar Lifesciences Limited
Nectar Lifesciences Limited is an India-based pharmaceutical company. The Company's business areas include active pharmaceutical ingredients (APIs) and intermediates, formulations/finished dosage formulations (FDF), menthol and mint derivatives, and empty hard gelatin capsules. The Company is engaged in the manufacturing of oral and sterile cephalosporin products. Its oral cephalosporins include cefixime, cefurozime axetil crystalline, cefuroxime axetil amorphous, cedpodoxime proxetil, cefprozil and cefdinir. Its sterile cephalosporins include cefotaxime sodium, ceftriaxone sodium, cefuroxime sodium, cefazolin sodium, ceftazidime pentahydrate and cefepime arginine. Its capacities include cefixime, cefuroxime axetil amorphous, cefuroxime axetil crystalline, cefotaxime sodium and ceftriaxone sodium. The Company offers contract manufacturing capabilities for solid dosage forms, such as tablets, capsules, dry powder oral suspension and granules and injectable for cephalosporins.
Employees
111
Date Price Change Volume
26-09-02 12.31 +1.48% 306,974
26-09-01 ₹12.13 -3.27% 284,172
26-08-31 ₹12.54 +0.56% 227,798
26-08-28 ₹12.47 -4.66% 468,735
26-08-27 ₹13.08 +4.98% 1,022,442
  1. Stock Market
  2. Stocks
  3. NECLIFE Stock